Prevention of lethal respiratory vaccinia infections in mice with interferon-α and interferon-γ

FEMS Immunology and Medical Microbiology

Volumn 40, Issue 3, 2004, Pages 201-206

  Liu, Ge ^a   Zhai, Qingzhu ^a   Schaffner, Dustin J ^a   Wu, Aiguo ^a   Yohannes, Adiamseged ^a   Robinson, Tanisha M ^a   Maland, Matt ^b   Wells, Jay ^c   Voss, Thomas G ^c   Bailey, Charlie ^a,b   Alibek, Ken ^a,b  

^a Advanced Biosystems Inc   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

Antiviral; Interferon ; Interferon ; Poxvirus; Vaccinia virus

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; VACCINIA; VACCINIA VIRUS; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; INTERFERON TYPE II; INTERFERON-ALPHA; MICE; PLAQUE ASSAY; RESPIRATORY TRACT INFECTIONS; SURVIVAL ANALYSIS; VACCINIA; VACCINIA VIRUS; VIRUS REPLICATION;

EID: 12144288731     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00358-4     Document Type: Article

References (38)

1. Esposito, J.J. and Fenner, F. (2001) Poxviruses. In: Fields Virology (Knipe, D.M. and Howley, P.M., Eds.), pp. 2885-2921. Lippincott William&Wilkings, Philadelphia, PA.
2. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., Hauer J., Layton M., McDade J., Osterholm M.T., O'Toole T., Parker G., Perl T., Russell P.K., Tonat K. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. J. Am. Med. Assoc. 281:1999;2127-2137.
3. van den Broek M.F., Muller U., Huang S., Zinkernagel R.M., Aguet M. Immune defense in mice lacking type I and/or type II interferon receptors. Immunol. Rev. 148:1995;5-18.
4. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., Vilcek J., Zinkernagel R.M., Aguet M. Immune response in mice that lack the interferon-gamma receptor. Science. 259:1993;1742-1745.
5. Morrill J.C., Jennings G.B., Cosgriff T.M., Gibbs P.H., Peters C.J. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha. Rev. Infect. Dis. 11:(Suppl. 4):1989;S815-S825.
6. Moradpour D., Blum H.E. Current and evolving therapies for hepatitis C. Eur. J. Gastroenterol. Hepatol. 11:1999;1199-1202.
7. Tignor G.H., Kende M., Hanham C.A. Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Ann. N. Y. Acad. Sci. 653:1992;334-343.
8. Earl, P.L., Cooper, N., Wyatt, L.S., Moss, B. and Carroll, M.W. (1998) Preparation of cell cultures and vaccinia virus stocks. In: Current Protocols in Molecular Biology (Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K., Eds.), Vol. 3, pp. 16.16.1-16.16.5. Wiley, New York.
9. Earl, P.L., Cooper, N., Wyatt, L.S. and Moss, B. (1998) Titration of vaccinia virus stocks by plaque assay. In: Current Protocols in Molecular Biology (Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A. and Struhl, K., Eds.), Vol. 3, pp. 16.16.5-16.16.6. Wiley, New York.
10. Weiss J., Zimmermann F. Tribromoethanol (Avertin) as an anaesthetic in mice. Lab. Anim. 33:1999;192-193.
11. Smee D.F., Bailey K.W., Sidwell R.W. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:2001;71-76.
12. Altman, D.G. (1991) Practical Statistics for Medical Research, 611 pp. Chapman and Hall, New York.
13. Alcami A., Smith G.L. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell. 71:1992;153-167.
14. Reed L.J., Meunch H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:1938;493-497.
15. Deonarain R., Alcami A., Alexiou M., Dallman M.J., Gewert D.R., Porter A.C. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J. Virol. 74:2000;3404-3409.
16. De Clercq E., De Somer P. Effect of interferon, polyacrylic acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl. Microbiol. 16:1968;1314-1319.
17. Weimar W., Stitz L., Billiau A., Cantell K., Schellekens H. Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. J. Gen. Virol. 48:1980;25-30.
18. Brooks T.J., Phillpotts R.J. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. Antivir. Res. 41:1999;57-64.
19. Lukaszewski R.A., Brooks T.J. Pegylated alpha interferon is an effective treatment for virulent venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J. Virol. 74:2000;5006-5015.
20. Fleischmann W.R. Jr., Koren S. Systemic effects of orally administered interferons and interleukin-2. J. Interferon Cytokine Res. 19:1999;829-839.
21. Tabata Y., Matsui Y., Uno K., Sokawa Y., Ikada Y. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver. J. Interferon Cytokine Res. 19:1999;287-292.
22. Angel J., Franco M.A., Greenberg H.B., Bass D. Lack of a role for type I and type II interferons in the resolution of rotavirus-induced diarrhea and infection in mice. J. Interferon Cytokine Res. 19:1999;655-659.
23. Katze M.G., He Y., Gale M. Viruses and interferon: A fight for supremacy. Nat. Rev. Immunol. 2:2002;675-687.
24. Biron, C.A. and Sen, G.C. (2001) Interferons and Other Cytokines. In: Fundamental Virology (Knipe, D.M. and Howley, P.M., Eds.), pp. 321-352. Lippincott William&Wilkings, Philadelphia, PA.
25. Kontsek P., Kontsekova E. Forty years of interferon. Acta Virol. 41:1997;349-353.
26. Fennie E.H., Lie Y.S., Low M.A., Gribling P., Anderson K.P. Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-gamma treatment. Antivir. Res. 10:1988;27-39.
27. Haagmans B.L., Van Der Meide P.H., Stals F.S., van den Eertwegh A.J., Claassen E., Bruggeman C.A., Horzinek M.C., Schijns V.E. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon. J. Virol. 68:1994;2305-2312.
28. Wille A., Gessner A., Lother H., Lehmann-Grube F. Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination. Eur. J. Immunol. 19:1989;1283-1288.
29. Lucchiari M.A., Martin J.P., Modolell M., Pereira C.A. Acquired immunity of A/J mice to mouse hepatitis virus 3 infection: dependence on interferon-gamma synthesis and macrophage sensitivity to interferon-gamma. J. Gen. Virol. 72:1991;1317-1322.
30. Lucchiari M.A., Modolell M., Eichmann K., Pereira C.A. In vivo depletion of interferon-gamma leads to susceptibility of A/J mice to mouse hepatitis virus 3 infection. Immunobiology. 185:1992;475-482.
31. Karupiah G., Fredrickson T.N., Holmes K.L., Khairallah L.H., Buller R.M. Importance of interferons in recovery from mousepox. J. Virol. 67:1993;4214-4226.
32. Morrill J.C., Czarniecki C.W., Peters C.J. Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. J. Interferon Res. 11:1991;297-304.
33. Zhou A., Chen Z., Rummage J.A., Jiang H., Kolosov M., Kolosova I., Stewart C.A., Leu R.W. Exogenous interferon-gamma induces endogenous synthesis of interferon-alpha and -beta by murine macrophages for induction of nitric oxide synthase. J. Interferon Cytokine Res. 15:1995;897-904.
34. Karupiah G., Xie Q.W., Buller R.M., Nathan C., Duarte C., MacMicking J.D. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 261:1993;1445-1448.
35. Vilcek J. Adverse effects of interferon in virus infections, autoimmune diseases and acquired immunodeficiency. Prog. Med. Virol. 30:1984;62-77.
36. Ezekowitz R.A., Dinauer M.C., Jaffe H.S., Orkin S.H., Newburger P.E. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N. Engl. J. Med. 319:1988;146-151.
37. Sechler J.M., Malech H.L., White C.J., Gallin J.I. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc. Natl. Acad. Sci. USA. 85:1988;4874-4878.
38. Bektemirov T.A., Burgasova M.P., Kuznetsov V.P., Rozina E.E., Andzhaparidze O.G. Smallpox vaccination with protection by interferon and an interferon inducer. Vopr. Virusol. 25:1980;76-78.